X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
APH-0812, a combination therapy consisting of PKC agonists with or without HDAC inhibitors, is designed to reactivate latent HIV reservoirs so that HIV can be eliminated by antiviral therapy and eradicated from the body.
Lead Product(s): APH-0812,Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: APH-0812
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
Bryoid, Bryostatin-23, is a highly potent nanomolar activator of α-secretase activity in neuroblastoma cell models, being effective than the canonical Bryostatin-1 at increasing activity of all protein kinase C isoforms, particularly the novel PKC isoforms, delta and epsilon.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021
Details:
The combination therapeutic consists of biodegradable polymer nanospheres co-encapsulating a Bryoid and a Retinoid to improve synergistically alpha-secretase (α-secretase) production and reduce -amyloid plaque generation.
Lead Product(s): Bryostatin-1,Tretinoin
Therapeutic Area: Neurology Product Name: APH-1104
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
